Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 2, Issue 17
September 11 2018
Issue Cover

Table of Contents

Clinical Trials and Observations

Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies
Clinical Trials & Observations
Alexander Röth,Scott T. Rottinghaus,Anita Hill,Eric S. Bachman,Jin Seok Kim,Hubert Schrezenmeier,Louis Terriou,Álvaro Urbano-Ispizua,Richard A. Wells,Jun Ho Jang,Austin G. Kulasekararaj,Jeff Szer,Rasha Aguzzi,Andrew I. Damokosh,Lori Shafner,Jong Wook Lee
View Articletitled, Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies
Supplemental data

Immunobiology and Immunotherapy

Enhancing immunotherapy of STING agonist for lymphoma in preclinical models
Adrienne Sallets,Sophie Robinson,Adel Kardosh,Ronald Levy
View Articletitled, Enhancing immunotherapy of STING agonist for lymphoma in preclinical models
Supplemental data

Lymphoid Neoplasia

STAT5 is essential for IL-7–mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells
Daniel Ribeiro,Alice Melão,Ruben van Boxtel,Cristina I. Santos,Ana Silva,Milene C. Silva,Bruno A. Cardoso,Paul J. Coffer,João T. Barata
View Articletitled, STAT5 is essential for IL-7–mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells
Supplemental data
Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS
Takeshi Sugio,Kohta Miyawaki,Koji Kato,Kensuke Sasaki,Kyohei Yamada,Javeed Iqbal,Toshihiro Miyamoto,Koichi Ohshima,Takahiro Maeda,Hiroaki Miyoshi,Koichi Akashi
View Articletitled, Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS
Supplemental data

Platelets and Thrombopoiesis

Cobalt hematoporphyrin inhibits CLEC-2–podoplanin interaction, tumor metastasis, and arterial/venous thrombosis in mice
Nagaharu Tsukiji,Makoto Osada,Tomoyuki Sasaki,Toshiaki Shirai,Kaneo Satoh,Osamu Inoue,Norihiko Umetani,Chihiro Mochizuki,Tamio Saito,Soichi Kojima,Hideyuki Shinmori,Yukio Ozaki,Katsue Suzuki-Inoue
View Articletitled, Cobalt hematoporphyrin inhibits CLEC-2–podoplanin interaction, tumor metastasis, and arterial/venous thrombosis in mice
Supplemental data

Thrombosis and Hemostasis

Alterations in platelet secretion differentially affect thrombosis and hemostasis
Smita Joshi,Meenakshi Banerjee,Jinchao Zhang,Akhil Kesaraju,Irina D. Pokrovskaya,Brian Storrie,Sidney W. Whiteheart
View Articletitled, Alterations in platelet secretion differentially affect thrombosis and hemostasis
Supplemental data

Transplantation

Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide
Laura K. Schoch,Kenneth R. Cooke,Nina D. Wagner-Johnston,Ivana Gojo,Lode J. Swinnen,Philip Imus,Ephraim J. Fuchs,Mark Levis,Richard F. Ambinder,Richard J. Jones,Douglas E. Gladstone
View Articletitled, Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide

Errata

Wu V, Moshier E, Leng S, et al. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. Blood Adv. 2018;2(12):1470-1479.
View Articletitled, Wu V, Moshier E, Leng S, et al. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. <em>Blood Adv</em>. 2018;2(12):1470-1479.
Espinoza JL, Elbadry MI, Chonabayashi K, et al. Hematopoiesis by iPSC-derived hematopoietic stem cells of aplastic anemia that escape cytotoxic T-cell attack. Blood Adv. 2018;2(4):390-400.
View Articletitled, Espinoza JL, Elbadry MI, Chonabayashi K, et al. Hematopoiesis by iPSC-derived hematopoietic stem cells of aplastic anemia that escape cytotoxic T-cell attack. <em>Blood Adv.</em> 2018;2(4):390-400.

Clinical Trials and Observations

Is a matched unrelated donor search needed for all allogeneic transplant candidates?
Clinical Trials & Observations
Stefan O. Ciurea,Maria Cecilia Borges Bittencourt,Denái R. Milton,Kai Cao,Piyanuch Kongtim,Gabriela Rondon,Julianne Chen,Marina Konopleva,Jorge M. Ramos Perez,Mohammed F. El Shazly,Majdi Aljadayeh,Michele Alvarez,Jin Im,Gheath Al-Atrash,Rohtesh Mehta,Uday Popat,Qaiser Bashir,Betul Oran,Chitra M. Hosing,Issa F. Khouri,Partow Kebriaei,Richard E. Champlin
Key Points

  • Race, haplotype frequency, and disease status at time of MUD search influence the probability of identifying a MUD/receiving a transplant.

  • Patients with a low likelihood of receiving a MUD transplant may proceed to a haploidentical transplant as soon as indicated.

View Articletitled, Is a matched unrelated donor search needed for all allogeneic transplant candidates?
Supplemental data

Platelets and Thrombopoiesis

A β1-tubulin–based megakaryocyte maturation reporter system identifies novel drugs that promote platelet production
Hideya Seo,Si Jing Chen,Kazuya Hashimoto,Hiroshi Endo,Yohei Nishi,Akira Ohta,Takuya Yamamoto,Akitsu Hotta,Akira Sawaguchi,Hideki Hayashi,Noritaka Koseki,George J. Murphy,Kazuhiko Fukuda,Naoshi Sugimoto,Koji Eto
Key Points

  • β1-tubulin–Venus reporter megakaryocyte cell line enabled high-throughput drug screening by monitoring megakaryocyte maturation.

  • The identified compounds, Wnt-C59 and TCS 359, induced megakaryocyte maturation under feeder-free conditions through distinct mechanisms.

View Articletitled, A β1-tubulin–based megakaryocyte maturation reporter system identifies novel drugs that promote platelet production
Supplemental data

Review Article

Deciphering the differentiation trajectory from hematopoietic stem cells to mast cells
Jennine Grootens,Johanna S. Ungerstedt,Gunnar Nilsson,Joakim S. Dahlin
View Articletitled, Deciphering the differentiation trajectory from hematopoietic stem cells to mast cells
All Issues

Advertisement intended for health care professionals

Time to revisit reduced-dose radiotherapy for PCNSL?
Lin A, Brown S, Chinapen S, et al. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant. Blood Adv. 2023;7(23):7153-7160.
Jalink M, Jacobs CF, Khwaja J, et al. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv. 2024;8(11):2622-2634.
Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes
Retreatment of multiple myeloma with previously refractory drugs

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals